Chronic visceral acid sphingomyelinase deficiency

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:77293OMIM:607616E75.2
Who is this for?
Show terms as
1Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Chronic visceral acid sphingomyelinase deficiency (ASMD) — also known as Niemann-Pick disease type B, or non-neuronopathic Niemann-Pick disease — is a rare inherited condition caused by a shortage of an enzyme called acid sphingomyelinase. This enzyme normally breaks down a fatty substance called sphingomyelin inside cells. When it does not work properly, sphingomyelin builds up in organs throughout the body, especially the liver, spleen, and lungs. Unlike the more severe type A form, type B (chronic visceral ASMD) mainly affects the organs rather than the brain and nervous system, though some patients do experience mild neurological involvement. The most noticeable effects are an enlarged spleen and liver, which can cause abdominal discomfort and a swollen belly. Lung involvement is also common and can lead to breathing difficulties, reduced exercise tolerance, and frequent respiratory infections. Many patients also have abnormal cholesterol and lipid levels in the blood, which raises the risk of heart disease over time. Low blood cell counts due to an overactive spleen can cause fatigue, easy bruising, and increased risk of infections. For many years, treatment was only supportive — managing symptoms rather than the underlying cause. However, olipudase alfa (brand name Xenpozyme), an enzyme replacement therapy, was approved by the FDA in 2022 and represents a major advance. It directly replaces the missing enzyme and has been shown to reduce organ enlargement and improve lung function. With proper management, many people with chronic visceral ASMD can live into adulthood, though ongoing monitoring and specialist care are essential.

Also known as:

Key symptoms:

Enlarged spleen (splenomegaly) causing a swollen or uncomfortable bellyEnlarged liver (hepatomegaly)Breathing difficulties and reduced ability to exerciseFrequent lung infections or pneumoniaLow red blood cell count (anemia) causing tiredness and pale skinLow platelet count leading to easy bruising or bleedingLow white blood cell count increasing infection riskAbnormal cholesterol and blood fat levelsDelayed growth or short stature in childrenMild neurological symptoms in some patients (such as balance problems)Cherry-red spot in the eye (less common in type B than type A)Bone pain or reduced bone densityFatigue and low energy

Clinical phenotype terms (47)— hover any for plain English
HypersplenismHP:0001971Abnormal circulating lipid concentrationHP:0003119Increased LDL cholesterol concentrationHP:0003141Decreased HDL cholesterol concentrationHP:0003233Interstitial pneumonitisHP:0006515Progressive pulmonary function impairmentHP:0006520Abnormal pulmonary interstitial morphologyHP:0006530Cherry red spot of the maculaHP:0010729Abnormal blood gas levelHP:0012415
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Chronic visceral acid sphingomyelinase deficiency.

View clinical trials →

No actively recruiting trials found for Chronic visceral acid sphingomyelinase deficiency at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Chronic visceral acid sphingomyelinase deficiency community →

Specialists

1 foundView all specialists →
FM
Forbes D Porter, M.D.
Bethesda, Maryland
Specialist

Rare Disease Specialist

PI on 14 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Chronic visceral acid sphingomyelinase deficiency.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Chronic visceral acid sphingomyelinase deficiencyForum →

No community posts yet. Be the first to share your experience with Chronic visceral acid sphingomyelinase deficiency.

Start the conversation →

Latest news about Chronic visceral acid sphingomyelinase deficiency

No recent news articles for Chronic visceral acid sphingomyelinase deficiency.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Am I a candidate for olipudase alfa (Xenpozyme) enzyme replacement therapy, and what would the treatment schedule look like?,How severely are my liver, spleen, and lungs affected right now, and how will we track changes over time?,Should my family members be tested to see if they are carriers or affected?,What activities or sports should I or my child avoid because of the enlarged spleen?,Are there any clinical trials I should know about for new treatments?,What signs or symptoms should prompt me to go to the emergency room?,How will this condition affect growth and development in my child long-term?

Common questions about Chronic visceral acid sphingomyelinase deficiency

What is Chronic visceral acid sphingomyelinase deficiency?

Chronic visceral acid sphingomyelinase deficiency (ASMD) — also known as Niemann-Pick disease type B, or non-neuronopathic Niemann-Pick disease — is a rare inherited condition caused by a shortage of an enzyme called acid sphingomyelinase. This enzyme normally breaks down a fatty substance called sphingomyelin inside cells. When it does not work properly, sphingomyelin builds up in organs throughout the body, especially the liver, spleen, and lungs. Unlike the more severe type A form, type B (chronic visceral ASMD) mainly affects the organs rather than the brain and nervous system, though some

How is Chronic visceral acid sphingomyelinase deficiency inherited?

Chronic visceral acid sphingomyelinase deficiency follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Which specialists treat Chronic visceral acid sphingomyelinase deficiency?

1 specialists and care centers treating Chronic visceral acid sphingomyelinase deficiency are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.